MA56550A - Formes solides de tert-butyl (s)-2-((2s,3r)-1-amino-3-hydroxy-1-oxobu tan-2-yl)-1-oxo -2, 5-diazaspiro[3,4]octane-5-carboxylate et leurs procédés de préparation - Google Patents

Formes solides de tert-butyl (s)-2-((2s,3r)-1-amino-3-hydroxy-1-oxobu tan-2-yl)-1-oxo -2, 5-diazaspiro[3,4]octane-5-carboxylate et leurs procédés de préparation

Info

Publication number
MA56550A
MA56550A MA056550A MA56550A MA56550A MA 56550 A MA56550 A MA 56550A MA 056550 A MA056550 A MA 056550A MA 56550 A MA56550 A MA 56550A MA 56550 A MA56550 A MA 56550A
Authority
MA
Morocco
Prior art keywords
diazaspiro
octane
carboxylate
oxo
tert
Prior art date
Application number
MA056550A
Other languages
English (en)
Inventor
Danny T Ding
Shaoxin Feng
William R Perrault
Xiaoda Yuan
Original Assignee
Naurex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Naurex Inc filed Critical Naurex Inc
Publication of MA56550A publication Critical patent/MA56550A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA056550A 2019-06-24 2020-06-23 Formes solides de tert-butyl (s)-2-((2s,3r)-1-amino-3-hydroxy-1-oxobu tan-2-yl)-1-oxo -2, 5-diazaspiro[3,4]octane-5-carboxylate et leurs procédés de préparation MA56550A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962865826P 2019-06-24 2019-06-24

Publications (1)

Publication Number Publication Date
MA56550A true MA56550A (fr) 2022-04-27

Family

ID=74060350

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056550A MA56550A (fr) 2019-06-24 2020-06-23 Formes solides de tert-butyl (s)-2-((2s,3r)-1-amino-3-hydroxy-1-oxobu tan-2-yl)-1-oxo -2, 5-diazaspiro[3,4]octane-5-carboxylate et leurs procédés de préparation

Country Status (12)

Country Link
US (1) US20220267341A1 (fr)
EP (1) EP3986399A4 (fr)
JP (1) JP2022539342A (fr)
KR (1) KR20220061088A (fr)
CN (1) CN114364380A (fr)
AU (1) AU2020304001A1 (fr)
BR (1) BR112021026380A2 (fr)
CA (1) CA3144600A1 (fr)
IL (1) IL289198A (fr)
MA (1) MA56550A (fr)
MX (1) MX2022000069A (fr)
WO (1) WO2020263847A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202110852A (zh) * 2019-06-24 2021-03-16 美商諾雷克斯股份有限公司 用於產生二氮雜螺內醯胺化合物之方法及中間物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080024536A (ko) * 2005-06-21 2008-03-18 아지노모토 가부시키가이샤 페닐알라닌 유도체의 결정, 이의 제조방법 및 이의 용도
MX2011003015A (es) * 2008-09-18 2011-11-18 Univ Northwestern Moduladores del receptor de n-metil-d-aspartato, y usos de los mismos.
BR112015018092A2 (pt) * 2013-01-29 2017-07-18 Naurex Inc moduladores de receptor de nmda de espiro-lactama e usos dos mesmos
LT3514158T (lt) * 2013-01-29 2023-02-10 Aptinyx Inc. Spirolaktaminiai nmda receptoriaus moduliatoriai ir jų panaudojimas
WO2017172565A1 (fr) * 2016-03-28 2017-10-05 Takeda Pharmaceutical Company Limited Formes cristallines de 2-[(2s)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-méthyl-1h-pyrazol-4-yl)thiéno[3,2-d]pyrimidin-4(3h)-one hémihydratée
MX2018014202A (es) * 2016-05-19 2019-06-20 Aptinyx Inc Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos.
TW202110852A (zh) * 2019-06-24 2021-03-16 美商諾雷克斯股份有限公司 用於產生二氮雜螺內醯胺化合物之方法及中間物

Also Published As

Publication number Publication date
IL289198A (en) 2022-02-01
WO2020263847A1 (fr) 2020-12-30
KR20220061088A (ko) 2022-05-12
CN114364380A (zh) 2022-04-15
AU2020304001A1 (en) 2022-01-27
EP3986399A4 (fr) 2023-06-07
MX2022000069A (es) 2022-05-24
JP2022539342A (ja) 2022-09-08
US20220267341A1 (en) 2022-08-25
BR112021026380A2 (pt) 2022-05-10
EP3986399A1 (fr) 2022-04-27
CA3144600A1 (fr) 2020-12-30

Similar Documents

Publication Publication Date Title
WO2016044556A3 (fr) Inhibiteurs d'arginine méthyltransférase et leurs utilisations
EP3934652A4 (fr) Composés, compositions et procédés pour le traitement d'une maladie
WO2016164675A8 (fr) Composés quinazoline substitués et leurs procédés d'utilisation
WO2015200680A8 (fr) Inhibiteurs de prmt5 et leurs utilisations
MD3442972T2 (ro) Inhibitori ai bromodomeniului
MA49752A (fr) Procédés de préparation de composés de pyrrolidine
EP1868628A4 (fr) Composes, compositions et methodes de traitement des infections a poxvirus
PH12018500653A1 (en) Salts and solid forms of monobactam antibiotic
UA91560C2 (ru) Соединения ряда изоиндолимидов, их композиция и применение
WO2017191130A3 (fr) Inhibiteurs d'arginase et leurs applications thérapeutiques
MA54091A (fr) Composés, compositions pharmaceutiques, procédés de préparation de composés et leur utilisation en tant qu'inhibiteurs de kinase atr
MX2021009806A (es) Ésteres de ácidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y métodos para usar los mismos.
MA55082A (fr) Compositions, procédés, et kits pour l'administration de polyribonucléotides
EA202190532A1 (ru) Ингибиторы аргиназы и способы их применения
MA51307A (fr) Compositions laitières fermentées et procédés de préparation de celles-ci
MA56132A (fr) Procédés de purification d'anticorps et compositions associées
MA56550A (fr) Formes solides de tert-butyl (s)-2-((2s,3r)-1-amino-3-hydroxy-1-oxobu tan-2-yl)-1-oxo -2, 5-diazaspiro[3,4]octane-5-carboxylate et leurs procédés de préparation
EP4031130A4 (fr) Compositions pour le traitement de tumeurs solides
EP3956346A4 (fr) Nouveaux composés radiomarqués diagnostiques et thérapeutiques ciblant cxcr4
MA51510A (fr) Procédés de préparation de dérivés d'indolinobenzodiazépine
MA50862A (fr) Procédés de réduction des effets secondaires d'une thérapie par conjugués médicament anticorps anti-cd30
WO2019109067A3 (fr) Promédicaments à base de créatine, compositions et procédés d'utilisation associés
MA50630A (fr) Procédé de préparation de dérivés d'alpha-carboxamide de pyrrolidine
IL272034B (en) Process for preparing n-((1r, 2s, 5r)-5-(tert-butylamino)-2-((s)-3-(7-tert-butylpyrazolo[1,a-5][1, 3, 5) Triazine-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide
GB201907547D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of hepatitis B